Leptin: The Satiety Hormone and the Puzzle of Leptin Resistance

Leptin, discovered in 1994, transformed how scientists think about body fat. Before leptin, adipose tissue was viewed mostly as inert storage. Leptin revealed fat as an endocrine organ that actively reports on the body's energy reserves. The name comes from the Greek leptos, meaning thin — a nod to what happens when the hormone is missing: animals and the rare humans lacking functional leptin develop severe, early-onset obesity driven by relentless hunger.

What leptin is

Leptin is a protein hormone (an adipokine) secreted mainly by white adipose tissue in rough proportion to fat mass. Circulating leptin therefore acts as a long-term signal of how much energy the body has stored. It travels to the brain and binds leptin receptors concentrated in the hypothalamus, the region that integrates signals governing hunger, satiety, and energy expenditure.

The core logic is a feedback loop. When fat stores are ample, leptin rises and tells the brain that energy is sufficient, dampening appetite and permitting normal energy expenditure. When fat stores fall — during fasting, dieting, or starvation — leptin drops sharply, and the brain responds by increasing hunger and conserving energy. This makes leptin at least as important as a starvation signal as a satiety signal; the fall in leptin during weight loss is a powerful driver of the rebound hunger that undermines diets.

Leptin and the appetite circuitry

In the hypothalamus, leptin acts on two opposing neuron populations in the arcuate nucleus. It stimulates POMC neurons, which produce the precursor to alpha-MSH and promote satiety through the melanocortin system, and it inhibits AgRP/NPY neurons, which drive hunger. The downstream melanocortin pathway — signaling through the MC4 receptor — is a critical node for body-weight regulation.

This circuitry is where leptin biology connects to modern obesity medicine. In rare genetic disorders that disrupt the leptin-melanocortin pathway, the MC4-receptor agonist setmelanotide can restore appetite control precisely because it acts downstream of the defect. That is a targeted, approved use in specific diagnosed conditions — not a general weight-loss tool — and it illustrates how understanding leptin's circuitry translates into rational drug design.

Leptin resistance: the central paradox

If leptin suppresses appetite, why are people with obesity — who have high fat mass and correspondingly high leptin — still hungry? This is the paradox of leptin resistance. In common obesity, leptin levels are elevated, yet the brain responds poorly to the signal. The system behaves as though it cannot "hear" the leptin that is present.

Several mechanisms are proposed, including impaired leptin transport across the blood-brain barrier, hypothalamic inflammation, and intracellular signaling suppression within leptin-responsive neurons. The practical consequence is important: giving extra leptin to people with common obesity generally does not work, because the problem is reduced sensitivity, not a shortage of hormone. Leptin therapy is effective only in the uncommon situation of true leptin deficiency. This is a major reason obesity is biologically difficult to reverse — the brain defends an elevated fat mass and resists signals that should curb intake.

Why obesity drugs target other pathways

Because leptin resistance limited leptin itself as a therapy, successful anti-obesity drugs have largely worked through different levers. GLP-1 receptor agonists such as semaglutide act on gut-brain satiety signaling and slow gastric emptying, producing appetite reduction that does not depend on restoring leptin sensitivity. These medicines have reshaped obesity treatment by engaging appetite circuits through a route leptin resistance does not block.

There is also research interest in "leptin sensitizers" — agents that might restore the brain's responsiveness to endogenous leptin rather than adding more hormone. This remains largely experimental. Mitochondrial and metabolic research peptides such as MOTS-c are studied for effects on metabolic flexibility and insulin sensitivity, but they are not leptin therapies, and claims that any peptide "fixes leptin resistance" in humans should be treated skeptically absent controlled data.

Leptin beyond appetite

Leptin's reach extends past hunger. It influences reproductive function (very low leptin from low body fat can suppress menstruation), immune function, bone metabolism, and the neuroendocrine adaptation to fasting. This breadth is why leptin is best understood as a master signal of energy availability that gates many energy-expensive processes, rather than a simple "eat less" switch.

Key takeaways

• Leptin is a fat-derived hormone that reports the body's energy stores to the hypothalamus, acting powerfully as a starvation signal when it falls during weight loss.
• It works through the leptin-melanocortin circuit (activating POMC/satiety neurons, inhibiting AgRP/hunger neurons); the MC4-receptor agonist setmelanotide targets this pathway in specific diagnosed disorders.
• In common obesity, high leptin coexists with leptin resistance, so extra leptin does not help — a key reason obesity resists reversal.
• Effective obesity drugs like GLP-1 agonists work through gut-brain satiety signaling rather than restoring leptin sensitivity; "leptin-fixing" peptide claims lack controlled human support.